Search

Validating questionnaires for social pharmacy research with smaller sample sizes can be unnecessarily time-consuming and costly, a solution to this is cognitive interviewing with 2 interviews per iteration. This paper shows how cognitive interviewing with pairs of interviews per iteration of the questionnaire can be used to identify overt and covert issues with comprehension, retrieval, judgment and response experienced by respondents when attempting to answer a question or navigate around the questionnaire. When used during questionnaire development in small scale social pharmacy research studies cognitive interviewing can reduce both respondent burden and response error and should result in more reliable survey results. The process of cognitive interviewing is illustrated by a case study from the development of the Perspectives on Progesterone questionnaire.

Objective To explore the influences on accessibility of compounded progesterone therapy for Australian women. Study design A cross-sectional survey of a stratified sample of Australian women who use progesterone only products using the ‘Perspectives on Progesterone’ questionnaire. Main outcome measures Principle components analysis (PCA) to determine components of access to progesterone treatment and multi-way analysis of variance to compare groups. Results Women using compounded progesterone were likely to have made at least one lifestyle adaptation (73%), and to have tried and stopped using at least one complementary and alternative medicine therapy (63%) or conventional hormone therapy (41%). PCA revealed six components of access to progesterone treatment: affordable, values natural treatments and is concerned about other treatments, conventionally available, perceived knowledge, values information gathered from a variety of sources, and rural & disadvantaged. The multifaceted nature of progesterone use illustrates that there are multiple aspects to use of non-conventional medicines. Women looking for non-conventional treatment are neither stupid nor uninformed, their understandings, based on experience and research, need to be addressed by health professionals while assessing their condition prior to discussing the risks and benefits of non-conventional medicines. Conclusion Access to compounded progesterone is multifaceted, and many of the women who use it have tried other treatments first. Despite the clinical ambivalence towards progesterone as an alternative for women who may have tried and rejected other treatments, including conventional hormone therapy, the women described in this paper are using it.

Objectives To determine factors influencing compounded progesterone products’ acceptability amongst Australian women who use them. Study design A cross-sectional survey of 366 women from all states of Australia who had been dispensed a compounded progesterone product, using the ‘Perspectives on Progesterone’ questionnaire. Main outcome measures Descriptive statistics and a logistic regression model of acceptability. Acceptability was measured by respondents’ willingness to recommend progesterone therapy to other women with a similar condition to their own and whether they had talked about their experience to other women. Results Australian women who use compounded progesterone tend to be highly educated. They were treating symptoms associated with menopause transition or hormone deficiency. The most common dosage form being used was transdermal cream. More than half the respondents reported improvement for mood swings or irritability (73%), foggy thinking (58%), hot flushes (56%), sleeping problems (55%), and anxiety (54%). Side effects were minimal with the weight gain being the most frequently reported (10%). There was no difference in symptom improvement between those who use progesterone alone or in combination with other hormones. The compounded progesterone acceptability model contains symptom improvement (very large effect size) perception that progesterone is natural and safe (large effect size), number of unexpected benefits (medium effect size) and treatment tailored to suit them (medium effect size). Concerns about other treatments or other treatments being ineffective did not contribute to acceptability. Conclusions Acceptance of compounded progesterone therapy depends on symptom improvement, perception of safety and naturalness and tailored therapy.

Progesterone treatment for menopausal symptoms is still controversial. Progesterone levels fall during menopause transition, therefore some menopausal women may benefit from progesterone therapy. A systematic review was conducted of studies published from 2001 reporting on progesterone use to treat symptoms associated with menopause or postmenopausal women. Fourteen data bases were searched using the search terms progesterone, menopause, aged, female and human; exclusions were breast cancer, animal and contraception. Thirteen studies were selected for inclusion (11 clinical trials, 1 cohort study and 1 qualitative study), evaluating progesterone effects on menopausal symptoms, bone, sleep, skin, cognition, plasma lipids and plaque progression. Most studies were of low methodological quality (GRADE low or very low). Progesterone improved vasomotor symptoms and sleep quality, with minimal risk. Large studies designed to identify confounders, such as hormone levels, menopausal status and metabolism are required to understand the place of progesterone in clinical practice.